137 related articles for article (PubMed ID: 34749266)
1. Structural basis for neutralization of enterovirus.
Huang KA
Curr Opin Virol; 2021 Dec; 51():199-206. PubMed ID: 34749266
[TBL] [Abstract][Full Text] [Related]
2. Enterovirus-Specific Anti-peptide Antibodies.
Poh CL; Kirk K; Chua HN; Grollo L
Methods Mol Biol; 2015; 1348():341-50. PubMed ID: 26424285
[TBL] [Abstract][Full Text] [Related]
3. Structural and functional analysis of protective antibodies targeting the threefold plateau of enterovirus 71.
Huang KA; Zhou D; Fry EE; Kotecha A; Huang PN; Yang SL; Tsao KC; Huang YC; Lin TY; Ren J; Stuart DI
Nat Commun; 2020 Oct; 11(1):5253. PubMed ID: 33067459
[TBL] [Abstract][Full Text] [Related]
4. Identification and characterization of a cross-neutralization epitope of Enterovirus 71.
Liu CC; Chou AH; Lien SP; Lin HY; Liu SJ; Chang JY; Guo MS; Chow YH; Yang WS; Chang KH; Sia C; Chong P
Vaccine; 2011 Jun; 29(26):4362-72. PubMed ID: 21501643
[TBL] [Abstract][Full Text] [Related]
5. Enterovirus A71 Containing Codon-Deoptimized VP1 and High-Fidelity Polymerase as Next-Generation Vaccine Candidate.
Tsai YH; Huang SW; Hsieh WS; Cheng CK; Chang CF; Wang YF; Wang JR
J Virol; 2019 Jul; 93(13):. PubMed ID: 30996087
[TBL] [Abstract][Full Text] [Related]
6. Establishment of a panel of in-house polyclonal antibodies for the diagnosis of enterovirus infections.
Kotani O; Iwata-Yoshikawa N; Suzuki T; Sato Y; Nakajima N; Koike S; Iwasaki T; Sata T; Yamashita T; Minagawa H; Taguchi F; Hasegawa H; Shimizu H; Nagata N
Neuropathology; 2015 Apr; 35(2):107-21. PubMed ID: 25263613
[TBL] [Abstract][Full Text] [Related]
7. Role of enterovirus infections in IgE sensitization.
Seiskari T; Kondrashova A; Tauriainen S; Knip M; Viskari H; Haapala AM; Hyöty H
J Med Virol; 2012 Feb; 84(2):268-71. PubMed ID: 22170547
[TBL] [Abstract][Full Text] [Related]
8. Cryo-EM structures reveal the molecular basis of receptor-initiated coxsackievirus uncoating.
Xu L; Zheng Q; Zhu R; Yin Z; Yu H; Lin Y; Wu Y; He M; Huang Y; Jiang Y; Sun H; Zha Z; Yang H; Huang Q; Zhang D; Chen Z; Ye X; Han J; Yang L; Liu C; Que Y; Fang M; Gu Y; Zhang J; Luo W; Zhou ZH; Li S; Cheng T; Xia N
Cell Host Microbe; 2021 Mar; 29(3):448-462.e5. PubMed ID: 33539764
[TBL] [Abstract][Full Text] [Related]
9. Immunological evaluation and comparison of different EV71 vaccine candidates.
Chou AH; Liu CC; Chang JY; Lien SP; Guo MS; Tasi HP; Hsiao KN; Liu SJ; Sia C; Wu SC; Lee MS; Hsiao CH; Wang JR; Chow YH; Chong P
Clin Dev Immunol; 2012; 2012():831282. PubMed ID: 23008736
[TBL] [Abstract][Full Text] [Related]
10. A new EV71 VP3 epitope in norovirus P particle vector displays neutralizing activity and protection in vivo in mice.
Jiang L; Fan R; Sun S; Fan P; Su W; Zhou Y; Gao F; Xu F; Kong W; Jiang C
Vaccine; 2015 Nov; 33(48):6596-603. PubMed ID: 26529072
[TBL] [Abstract][Full Text] [Related]
11. Serum Neutralization Assay for the Determination of Antibody Levels Against Non-Polio Enterovirus Strains in Central and Western Greece.
Fikatas A; Dimitriou TG; Kyriakopoulou Z; Tsachouridou O; Gartzonika C; Levidiotou-Stefanou S; Amoutzias GD; Markoulatos P
Viral Immunol; 2016 Sep; 29(7):444-50. PubMed ID: 27410516
[TBL] [Abstract][Full Text] [Related]
12. Antiviral Activity of a Llama-Derived Single-Domain Antibody against Enterovirus A71.
Huang PN; Wang HC; Hung HC; Tseng SN; Chang TY; Chou MY; Chen YJ; Wang YM; Shih SR; Hsu JT
Antimicrob Agents Chemother; 2020 Apr; 64(5):. PubMed ID: 32152074
[TBL] [Abstract][Full Text] [Related]
13. Identification of four neutralizing antigenic sites on the enterovirus D68 capsid.
Dai W; Li X; Liu Z; Zhang C
J Virol; 2023 Dec; 97(12):e0160023. PubMed ID: 38047678
[TBL] [Abstract][Full Text] [Related]
14. Combination of three virus-derived nanoparticles as a vaccine against enteric pathogens; enterovirus, norovirus and rotavirus.
Heinimäki S; Hankaniemi MM; Sioofy-Khojine AB; Laitinen OH; Hyöty H; Hytönen VP; Vesikari T; Blazevic V
Vaccine; 2019 Dec; 37(51):7509-7518. PubMed ID: 31585726
[TBL] [Abstract][Full Text] [Related]
15. Seroprevalence of Enterovirus A71 and Coxsackievirus A16 in Healthy People in Shandong Province, China.
Wang JX; Zhu SL; Wang J; Lin Y; Pei YW; Sun DP; Zhang Y; Wang XJ; Xu WB; Ding SJ
PLoS One; 2016; 11(9):e0162373. PubMed ID: 27611441
[TBL] [Abstract][Full Text] [Related]
16. Enterovirus virus-like-particle and inactivated poliovirus vaccines do not elicit substantive cross-reactive antibody responses.
Moss DL; Paine AC; Krug PW; Kanekiyo M; Ruckwardt TJ
PLoS Pathog; 2024 Apr; 20(4):e1012159. PubMed ID: 38662650
[TBL] [Abstract][Full Text] [Related]
17. Structure, Immunogenicity, and Protective Mechanism of an Engineered Enterovirus 71-Like Particle Vaccine Mimicking 80S Empty Capsid.
Wang X; Ku Z; Zhang X; Ye X; Chen J; Liu Q; Zhang W; Zhang C; Fu Z; Jin X; Cong Y; Huang Z
J Virol; 2018 Jan; 92(1):. PubMed ID: 29070691
[TBL] [Abstract][Full Text] [Related]
18. High-titred neutralizing antibodies to human enterovirus 71 preferentially bind to the N-terminal portion of the capsid protein VP1.
Tan CS; Cardosa MJ
Arch Virol; 2007; 152(6):1069-73. PubMed ID: 17318736
[TBL] [Abstract][Full Text] [Related]
19. Recombinant virus-like particle presenting a newly identified coxsackievirus A10 neutralization epitope induces protective immunity in mice.
Dai W; Xiong P; Zhang X; Liu Z; Chen J; Zhou Y; Ye X; Zhang C
Antiviral Res; 2019 Apr; 164():139-146. PubMed ID: 30817941
[TBL] [Abstract][Full Text] [Related]
20. Identification of conserved neutralizing linear epitopes within the VP1 protein of coxsackievirus A16.
Shi J; Huang X; Liu Q; Huang Z
Vaccine; 2013 Apr; 31(17):2130-6. PubMed ID: 23499595
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
